Patent details

EP4168008 Title: A COMBINATION OF BELZUTIFAN AND LENVATINIB FOR USE IN TREATING CANCER

Basic Information

Publication number:
EP4168008
PCT Application Number:
US2021038172
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP218287613
PCT Publication Number:
WO2021262563
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
A COMBINATION OF BELZUTIFAN AND LENVATINIB FOR USE IN TREATING CANCER
French Title of Invention:
UNE ASSOCIATION DU BELZUTIFAN ET DU LENVATINIB POUR SON UTILISATION DANS LE TRAITEMENT DU CANCER
German Title of Invention:
EINER KOMBINATION AUS BELZUTIFAN UND LENVATINIB ZUR VERWENDUNG BEI DER BEHANDLUNG VON KREBS
SPC Number:

Dates

Filing date:
21/06/2021
Grant date:
18/03/2026
EP Publication Date:
26/04/2023
PCT Publication Date:
30/12/2021
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
18/03/2026
EP B1 Publication Date:
18/03/2026
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
21/06/2041
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
11/03/2026
 
 

Name:
Eisai R&D Management Co., Ltd.
Address:
6-10 Koishikawa, 4-Chome Bunkyo-Ku, Tokyo 112-8088, Japan (JP)

Name:
Merck Sharp & Dohme LLC
Address:
126 East Lincoln Avenue, Rahway, New Jersey 07065, United States (US)

Inventor

1

Name:
WILLEMANN ROGERIO, Jaqueline
Address:
United States (US)

2

Name:
PERINI, Rodolfo Fleury
Address:
United States (US)

3

Name:
PINHEIRO, Elaine, M.
Address:
United States (US)

Priority

1

Priority Number:
202063042307 P
Priority Date:
22/06/2020
Priority Country:
United States (US)

2

Priority Number:
202163146915 P
Priority Date:
08/02/2021
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/47; A61K 31/277; A61P 35/04;

Publication

European Patent Bulletin

1

Issue number:
202612
Publication date:
18/03/2026
Description:
Grant (B1)

2

Issue number:
202616
Publication date:
15/04/2026
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
30/06/2026
Annual Fee Number:
6
Annual Fee Amount:
66 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages